Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.
Open Access
- 1 May 1991
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 88 (9) , 3535-3539
- https://doi.org/10.1073/pnas.88.9.3535
Abstract
The relationship between detrimental (cachectic) and beneficial (antitumor) effects of tumor necrosis factor (TNF) was studied in mice bearing murine tumors transfected to secrete human TNF. In vitro, the TNF-producing transfectants were resistant to the secreted TNF and grew at rates similar to those of untransfected cells or transfected cells that did not secrete TNF. However, tumors formed by the TNF-secreting cells in vivo remained much smaller than the nonsecreting (transfected and untransfected) tumors. This inhibition of tumor growth required only relatively low serum levels of TNF, persisted for many weeks, and was independent of T cells since it occurred in nude mice. Growth of the TNF-secreting tumors increased dramatically after treatment with anti-human TNF antibody, indicating that extracellular TNF secreted by the tumor cells was necessary for the tumor inhibition. Severe weight loss characteristic of cachexia only occurred in animals with very high serum TNF levels (250 pg/ml) and could be prevented or reversed by anti-TNF antibody treatment. These data are consistent with the existence of a therapeutic window in which persistent exposure to human TNF can lead to prolonged inhibition of tumor growth in the absence of T-cell immunity or severe weight loss and without development of resistant tumor variants.Keywords
This publication has 16 references indexed in Scilit:
- Endogenous cachectin/tumour necrosis factor-alpha production contributes to experimental cancer-associated cachexia.1989
- The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma.The Journal of Experimental Medicine, 1988
- The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.The Journal of Experimental Medicine, 1988
- Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.Proceedings of the National Academy of Sciences, 1987
- Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural ProbesHybridoma, 1987
- Tumors secreting human TNF/cachectin induce cachexia in miceCell, 1987
- Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.The Journal of Experimental Medicine, 1986
- Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.Proceedings of the National Academy of Sciences, 1986
- Identity of tumour necrosis factor and the macrophage-secreted factor cachectinNature, 1985
- An endotoxin-induced serum factor that causes necrosis of tumors.Proceedings of the National Academy of Sciences, 1975